# A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data

> **NCT01381523** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)
- **DRUG:** Single-entity oral triptans

## Key facts

- **NCT ID:** NCT01381523
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2013-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381523, "A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01381523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*